BMRN Stock Recent News
BMRN LATEST HEADLINES
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 11:30 AM EDT Company Participants Alexander Hardy - President, CEO & Director Brian Mueller - Executive VP of Finance, CFO & Principal Accounting Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman Head of Healthcare Research & Equity Analyst Good morning, everyone, and welcome to this good morning. Welcome to Morgan Stanley Global Healthcare Conference.
On Saturday, BioMarin Pharmaceutical Inc. BMRN released new Phase 3 PEGASUS study results on Saturday.
New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated with PALYNZIQ BioMarin's planned submission to global health authorities on track for second half of 2025 SAN RAFAEL, Calif. , Sept. 6, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data characterizing the efficacy and safety of PALYNZIQ ® (pegvaliase-pqpz) for the treatment of adolescents with phenylketonuria (PKU), which were presented at the 15th International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, Sept.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Olivia Brayer Research Analyst Okay. Great. Hey, good morning, everyone.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BioMarin's revenue growth is strong, with Q2 2025 revenues up 16% year-over-year and full-year guidance raised to $3.125–$3.2 billion. The Inozyme acquisition brings late-stage BMN 401 for ENPP1 deficiency, with pivotal phase 3 data expected in 1H 2026 and potential first-mover advantage. Voxzogo and Palynziq continue to drive growth, with label expansions and new pipeline candidates like BMN 333 poised to further bolster its pipeline.
On Tuesday, Biomarin Pharmaceutical Inc. BMRN reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.